You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 22, 2024

Bristol-myers Squibb Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for BRISTOL-MYERS SQUIBB, and when can generic versions of BRISTOL-MYERS SQUIBB drugs launch?

BRISTOL-MYERS SQUIBB has one approved drug.

There are five US patents protecting BRISTOL-MYERS SQUIBB drugs.

There are eighty-one patent family members on BRISTOL-MYERS SQUIBB drugs in thirty-one countries and nineteen supplementary protection certificates in sixteen countries.

Drugs and US Patents for Bristol-myers Squibb

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-001 Jul 24, 2015 DISCN Yes No 9,421,192 ⤷  Sign Up Y ⤷  Sign Up
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-001 Jul 24, 2015 DISCN Yes No 8,642,025 ⤷  Sign Up Y Y ⤷  Sign Up
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-003 Apr 13, 2016 DISCN Yes No 9,421,192 ⤷  Sign Up Y ⤷  Sign Up
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-002 Jul 24, 2015 DISCN Yes No 8,642,025 ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Bristol-myers Squibb Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2049522 122015000009 Germany ⤷  Sign Up PRODUCT NAME: DACLATASVIR UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, INSBESONDERE DACLATASVIR DIHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/939/001-004 20140822
2049522 2015C/006 Belgium ⤷  Sign Up DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE
2049522 1590007-9 Sweden ⤷  Sign Up PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REG. NO/DATE: EU/1/14/939 20140826
2049522 92635 Luxembourg ⤷  Sign Up PRODUCT NAME: DACLATASVIR ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES , EN PARTICULIER DICHLORHYDRATE DE DACLATASVIR. FIRST REGISTRATION: 20140826
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.